Synaptogenix | 10-Q: FY2025 Q1 EPS: USD 0.04

LB filings
2025.07.01 11:35
portai
I'm PortAI, I can summarize articles.

EPS: As of FY2025 Q1, the actual value is USD 0.04.

Segment Revenue

  • Synaptogenix, Inc. did not generate any operating revenues for the three months ended March 31, 2025 and 2024.

Operational Metrics

  • Net Income (Loss): The company reported net income of $385,169 for the three months ended March 31, 2025, compared to a net loss of $206,699 for the same period in 2024, representing an increase of 283.6%.
  • Research and Development Expenses: R&D expenses decreased significantly by 90.0% from $609,249 in 2024 to $60,816 in 2025.
  • General and Administrative Expenses: These expenses decreased by 6.8% from $1,082,245 in 2024 to $1,008,349 in 2025.

Cash Flow

  • Net Cash Used in Operating Activities: The company used $2,000,596 in operating activities for the three months ended March 31, 2025, compared to $1,831,541 for the same period in 2024.
  • Net Cash Used in Investing Activities: No cash was used in investing activities for the three months ended March 31, 2025, compared to $500,000 used in 2024.
  • Net Cash Used in Financing Activities: The company used $822,362 in financing activities for the three months ended March 31, 2025, compared to $0 in 2024.

Unique Metrics

  • Change in Fair Value of Warrant Liability: The company recorded a gain of $1,351,000 related to the change in fair value of the warrant liability for the three months ended March 31, 2025.
  • Change in Fair Value of Derivative Liability: The company recorded a loss of $79,000 related to the change in fair value of the derivative liability for the three months ended March 31, 2025.

Future Outlook and Strategy

  • Core Business Focus: The company is focused on developing Bryostatin-1 for the treatment of Alzheimer’s disease and other neurodegenerative diseases. It expects its current cash and cash equivalents to support its projected operating requirements for at least the next 12 months.
  • Non-Core Business: The company is exploring strategic alternatives through a special committee to enhance value for investors, including drug development platforms and new technologies.
  • Priority: The company anticipates needing additional capital to pursue further development projects beyond the ongoing Phase 2 trial of Bryostatin-1.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.